Second generation Chimeric Antigen Receptor (CAR) T-cells have revolutionised the treatment of B-cell and plasma cell malignancies, achieving potent and durable responses across a number of ...
CAR has the ability to specifically recognize target cells and activate NK cells to kill tumor cells. Therefore, the design and engineering of the CAR structure are crucial for CAR-NK therapeutic ...
CAR-T therapies are a new successful strategy for treating hematological malignancies. However, recent studies have demonstrated the limitations of such therapies, such as the occurrence of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback